Electronic Injector for use with most standard and prefilled syringes Copyright© September 2015

THE PROBLEM: No one likes injections or needles 80 drugs besides insulin are prescribed for self injection and 56 million prescriptions for these drugs were written in 2007.* *2007 NAMCS Data (National Ambulatory Medical Care Survey, U.S.) Self-injection requires skill, fortitude, and involves an amount of risk (improper positioning can cause bruising, tissue damage, incorrect dosage, and bent needles)

Hide the needle and syringe inside the injector Cue for physical orientation (tones, vibration) Suppress pain via TENS function (low electrical stimulus blocks pain sensation) Spoken instructions (audio cues and voice) Electronic motion control for gentle needle insertion, dispensing of medication, and needle retraction. Reminder timer for next injection (ringtone) How can we help?

THESE: Standard Syringes and Prefilled-Syringes Go In here Patent Pending

THE SOLUTION: InnoJect electronic injector simplifies and improves the injection process via motion control automation and pain suppression  Easy Top Loading.  Accommodates most any syringe and needle lengths up to 1-1/2 inches.  Motion control gently inserts needle and dispenses medication.  Needle is retracted after injection.  Provides audio queues plus directions in human voice of any language.  Electronically senses skin to ensure stability before allowing injection.  TENS function electronically suppresses pain from needle insertion.  Reminder timer plays ringtone when it’s time for next injection.  Professional model has sterile disposable needle shields for use with multiple patients.

Competitive Market & Weakness Insulin Pens (mechanical, manual needle insertion) Autoinjectors (spring fired, preloaded, single use, expensive) Autoinjectors (spring fired, loads limited range of syringes) Jet Injectors (not painless, limited to drugs approved for jet) Initial Target Market Home administered drugs which have one of the following: no injection aid require a larger needle are painful. These administered drugs totaled 13.7 million prescriptions in U.S. in 2007 (see next slide).

TOTAL US MARKET SIZE: 17.5 million projected customers 56 million self-injectable prescriptions in the U.S. annual.§ 35 million self-injectable prescriptions applicable to InnoJect usage.* 17.5 million potential customers per annum.** INITIAL TARGETED MARKET SHARE: 68,000 projected customers (MODEL 1) 13.7 million prescriptions are prime candidates for this market space.*** 6.8 million projected customers available for capture.** 1% capture rate = 68,000 InnoJects sold per annum U.S. INNOJECT: MARKET ANALYSIS & TRENDS IN US § 2007 NAMCS Data (National Ambulatory Medical Care Survey) and Insurance Survey for Drugs for Home Use by Blue Cross and Blue Shields 2007 *A percentage of the prescriptions for each drug applicable to our device, according to its specifics, is weighted and used to give a total potential market. **Assumes that half the prescriptions are refills. ***Initial projected market share is based upon the number of pharmaceutical drugs most likely prescribed along with the InnoJect device, is weighted and number calculated.

Medical facilities where NextGEN InnoJect model is utilized with multiple patients (1 device to multiple patients) International (underdeveloped countries) pharmaceutical drugs administered in treatment centers Immunizations stations Prefilled syringes market that are currently NOT adaptable to primary basic InnoJect model. Future Target Markets NOTE: 2.5 billion prefilled syringes used worldwide in 2011.

Market Entry Contracts with the industry principle(s) for marketing function may be: distributors syringe manufacturers drug manufacturers who wants to distinguish themselves by solving the “self-injection” problem for their product. Market Entrance Scenario 1.Self-Injectable drugs are prescribed by a physician. 2.The physician sees our client, the patient. 3.InnoJect (Class II medical device) requires prescription. 4.The InnoJect turns a standard syringe or prefilled syringe into an “autoinjector” with finesse, effectively making the prospect of “self injection” an easy and much less scary task. 5.Doctor solves patient’s self-injection problem by prescribing the InnoJect to the client along with prescribed self-injectable drug. 6.Client’s costs covered by insurance company (part of marketing plan).